Drawing for CYCLERION THERAPEUTICS

USPTO serial 88108819

CYCLERION THERAPEUTICS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
RUTLAND, BARBARA A
Law office
DIVISIONAL UNIT

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with CYCLERION THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Anessa Kramer

Anessa Kramer Honigman LLP39400 Woodward Avenue, Suite 101BLOOMFIELD HILLS, MI 48304UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds, namely, preparations that stimulate guanylate cyclases (sGC), increase the concentration of nitric oxide (NO), increase the concentration of cyclic guanosine monophosphate (cGMP), upregulate the NO-sGC-cGMP (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway, or utilize a synergistic interaction of the NO-sGC-cGMP (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway with a complementary signaling pathway; Pharmaceutical preparations, namely, pharmaceutical preparations and substances for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and woundsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Apr 17, 2023MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 17, 2023ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 8, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 7, 2022EX5GSOU EXTENSION 5 GRANTED—
Aug 31, 2022EXT5SOU EXTENSION 5 FILED—
Aug 31, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 2, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 28, 2022EX4GSOU EXTENSION 4 GRANTED—
Feb 28, 2022EXT4SOU EXTENSION 4 FILED—
Feb 28, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 16, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 14, 2021EX3GSOU EXTENSION 3 GRANTED—
Sep 14, 2021EXT3SOU EXTENSION 3 FILED—
Sep 14, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 10, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 8, 2021EX2GSOU EXTENSION 2 GRANTED—
Mar 8, 2021EXT2SOU EXTENSION 2 FILED—
Mar 8, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 19, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 15, 2020EX1GSOU EXTENSION 1 GRANTED—
May 15, 2020EXT1SOU EXTENSION 1 FILED—
May 15, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 14, 2020NOACCORRECTED NOA E-MAILED—
May 13, 2020DPCCDIVISIONAL PROCESSING COMPLETE—
May 12, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 26, 2020DRRRDIVISIONAL REQUEST RECEIVED—
Apr 26, 2020ERTDTEAS REQUEST TO DIVIDE RECEIVED—
Mar 17, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 21, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 21, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 1, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 16, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 16, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Dec 16, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 16, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 16, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 9, 2019GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jul 9, 2019GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 9, 2019CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 25, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 25, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 25, 2019ALIEASSIGNED TO LIE—
Jun 19, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 20, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 20, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 20, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 18, 2018DOCKASSIGNED TO EXAMINER—
Sep 17, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 11, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance